<DOC>
	<DOCNO>NCT00884416</DOCNO>
	<brief_summary>This phase I study evaluate safety tolerability Sorafenib combination Temodar radiation therapy patient newly diagnose high grade glioma ( glioblastoma , gliosarcoma , anaplastic astrocytoma anaplastic oligodendroglioma oligoastrocytoma ) . The mechanism action sorafenib , oral multikinase inhibitor , make interesting drug investigate treatment patient high grade glioma agent anti-angiogenic activity inhibits pathways Ras , Platelet-derived growth factor ( PDGF ) fms-like tyrosine kinase receptor-3 ( Flt-3 ) , potential target gliomas .</brief_summary>
	<brief_title>Sorafenib Newly Diagnosed High Grade Glioma</brief_title>
	<detailed_description>Up 18 patient include phase I study . The primary goal study establish maximum tolerate dose sorafenib use combination temozolomide radiation therapy . Secondary goal study include : response rate , time treatment failure , 6 month progression-free survival , event free survival overall survival . A correlative study investigate pharmacokinetics sorafenib use combination radiation therapy temozolomide .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histological documentation newly diagnose malignant glioma ECOG performance status 0 1 Age ≥18 Life expectancy least 12 week Hemoglobin ≥ 9.0 g/dl Granulocyte count ≥1.5 X 10^9/L Platelet count ≥100 X 10^9/L SGOT ≤ 2.5X upper limit normal ( ULN ) SGPT ≤ 2.5X upper limit normal ( ULN ) Alkaline phosphatase ≤4x ULN Serum creatinine ≤1.5X ULN Bilirubin ≤1.5X ULN Spontaneous PTINR/PTT &lt; 1.5x upper limit normal ( patient therapeutic anticoagulation allow participate . Patients must stable decrease dose corticosteroid least 2 week Patient first line treatment temozolomide radiotherapy adequate Prophylactic antiemetic , pentamidine inhalation / cotrimoxazole anticonvulsant allow All patient must sign write informed consent . Prior treatment high grade glioma Previous exposure Ras pathway inhibitor Other concurrent active malignancy ( exception cervical carcinoma situ non melanoma carcinoma skin , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry ) . Serious medical psychiatric illness would , opinion investigator , interfere prescribe treatment , include limited : Congestive heart failure &gt; NYHA class 2 , active CAD , cardiac arrythmias require antiarrythmic therapy uncontrolled hypertension within last 12 month Any condition limit patient 's judgment capacity History HIV infection , chronic hepatitis C B well clinically active infection ( &gt; grade 2 NCICTC version 3.0 ) History organ allograft Renal dialysis Evidence history bleed diathesis Major surgery within 4 week start study treatment , except neurosurgical resection Autologous bone marrow transplant stem cell rescue within 4 month study Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result . Medical condition prevents patient swallow pill Use biologic response modifier , GCSF within 3 week study entry . Pregnant breastfeed woman . Refusal use effective contraception . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial least 3 month administration study medication . Known suspected allergy investigational agent agent give association trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>high grade glioma</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>gliosarcoma</keyword>
	<keyword>anaplastic astrocytoma</keyword>
	<keyword>anaplastic oligoastrocytoma</keyword>
	<keyword>anaplastic oligodendroglioma</keyword>
	<keyword>phase I</keyword>
	<keyword>first line treatment</keyword>
	<keyword>sorafenib</keyword>
	<keyword>temozolomide</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>protein kinase inhibitor</keyword>
</DOC>